Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden

NCT07715396 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

230

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG: Tislelizumab
DRUG: Tislelizumab Combined With Chemotherapy
DRUG: Pembrolizumab

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]